Skip to main content

Migraine

This booklet is for you if:

  • you have or think you have migraines
  • you are a friend, relative or carer of someone who has migraines

This booklet explains the recommendations in a clinical guideline, produced by the Scottish Intercollegiate Guidelines Network (SIGN), about the use of medication to manage migraines. The clinical guidance is based on what we know from current medical research. It also gives advice based on the opinion of healthcare professionals who are trained on how best to manage your care.

If you would like to order copies of the booklet, please email sign@sign.ac.uk

We are happy to consider requests for our publications to be made available in other languages or formats. We ask you to complete a form to help us make a decision on whether to proceed. Factors affecting the decision include level of demand, cost to translate, availability of interpretation services, other format(s) available and subject matter of the publication.

⚠️IMPORTANT⚠️

In June 2024 the MHRA issued new safety measures for the use of topiramate during pregnancy due to risks to the unborn child:

Topiramate should not be used in women of childbearing potential unless the conditions of the Pregnancy Prevention Programme are fulfilled. This aims to ensure that all women of childbearing potential:

  • are using highly effective contraception
  • have a pregnancy test to exclude pregnancy before starting topiramate
  • are aware of the risks from use of topiramate.

Further information is available: Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention Programme

The guideline is under review to take account of this advice.

PAT 155, September 2022